# Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

> **NCT00122447** · NA · COMPLETED · sponsor: **Emory University** · enrollment: 84 (actual)

## Conditions studied

- Impaired Glucose Tolerance
- Prediabetic State

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Alpha lipoic acid
- **DRUG:** Olmesartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00122447
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2013-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122447, "Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00122447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*